Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

NCT05803395 · clinicaltrials.gov ↗
UNKNOWN
Status
954
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Collaborators